Christopher P. Loo
University of California, San Francisco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher P. Loo.
PLOS ONE | 2006
Fatema A. Legrand; Douglas F. Nixon; Christopher P. Loo; Erika Ono; Joan M. Chapman; Maristela Miyamoto; Ricardo Sobhie Diaz; Amélia Miyashiro Nunes dos Santos; Regina Célia de Menezes Succi; Jacob Abadi; Michael G. Rosenberg; Maria Isabel de Moraes-Pinto; Esper G. Kallas
Background In utero transmission of HIV-1 occurs on average in only 3%–15% of HIV-1-exposed neonates born to mothers not on antiretroviral drug therapy. Thus, despite potential exposure, the majority of infants remain uninfected. Weak HIV-1-specific T-cell responses have been detected in children exposed to HIV-1, and potentially contribute to protection against infection. We, and others, have recently shown that the removal of CD4+CD25+ T-regulatory (Treg) cells can reveal strong HIV-1 specific T-cell responses in some HIV-1 infected adults. Here, we hypothesized that Treg cells could suppress HIV-1-specific immune responses in young children. Methodology/Principal Findings We studied two cohorts of children. The first group included HIV-1-exposed-uninfected (EU) as well as unexposed (UNEX) neonates. The second group comprised HIV-1-infected and HIV-1-EU children. We quantified the frequency of Treg cells, T-cell activation, and cell-mediated immune responses. We detected high levels of CD4+CD25+CD127− Treg cells and low levels of CD4+ and CD8+ T cell activation in the cord blood of the EU neonates. We observed HIV-1-specific T cell immune responses in all of the children exposed to the virus. These T-cell responses were not seen in the cord blood of control HIV-1 unexposed neonates. Moreover, the depletion of CD4+CD25+ Treg cells from the cord blood of EU newborns strikingly augmented both CD4+ and CD8+ HIV-1-specific immune responses. Conclusions/Significance This study provides new evidence that EU infants can mount strong HIV-1-specific T cell responses, and that in utero CD4+CD25+ T-regulatory cells may be contributing to the lack of vertical transmission by reducing T cell activation.
Journal of Leukocyte Biology | 2008
Lishomwa C. Ndhlovu; Christopher P. Loo; Gerald Spotts; Douglas F. Nixon; Frederick Hecht
During the course of HIV‐1 infection, the status of immune activation has been determined to be a powerful indicator of disease progression. The immune system has adopted self‐regulatory mechanisms to counterbalance undesirable immune responses. CD25+CD4+ T regulatory (Treg) cells that express the transcription regulator, forkhead box P3 (FOXP3), play an important role in this immunosuppression. Using a combination of Treg cell discriminatory markers (FOXP3, CD25, CD127), we predicted that an expansion of Treg cell subsets would negatively correlate with immune activation during the early stages of HIV‐1 infection. We report that FOXP3+CD127lo expressing CD4+ T cells increases in primary HIV‐1 infection over time. Furthermore, the FOXP3+CD127lo CD4+ T cells may, in fact, reduce the levels of T cell activation following primary infection. It is interesting that the positive correlation between FOXP3+CD127lo CD4+ and CD25+CD127lo CD4+ T cells noted in HIV‐uninfected persons is not only lost but may also be reversed in early, chronic HIV‐1 infection. Unlike FOXP3+CD127lo CD4+, the level of FOXP3+CD25+CD127lo CD4+ T cells did not correlate with T cell activation, suggesting that these cells were not effective in reducing T cell activation. These observations suggest that different Treg populations may have different effects on reducing immune activation in HIV‐1 infection and that the FOXP3+CD127lo CD4+ T cell population may be particularly important in limiting immune activation.
Journal of Virology | 2007
John W. Northfield; Christopher P. Loo; Jason D. Barbour; Gerald Spotts; Frederick Hecht; Paul Klenerman; Douglas F. Nixon; Jakob Michaëlsson
ABSTRACT CD8+ T cells are believed to play an important role in the control of human immunodeficiency virus type 1 (HIV-1) infection. However, despite intensive efforts, it has not been possible to consistently link the overall magnitude of the CD8+ T-cell response with control of HIV-1. Here, we have investigated the association of different CD8+ memory T-cell subsets responding to HIV-1 in early infection with future control of HIV-1 viremia. Our results demonstrate that both a larger proportion and an absolute number of HIV-1-specific CD8+ CCR7− CD45RA+ effector memory T cells (TEMRA cells) were associated with a lower future viral load set point. In contrast, a larger absolute number of HIV-1-specific CD8+ CCR7− CD45RA− effector memory T cells (TEM) was not related to the viral load set point. Overall, the findings suggest that CD8+ TEMRA cells have superior antiviral activity and indicate that both qualitative and quantitative aspects of the CD8+ T-cell response need to be considered when defining the characteristics of protective immunity to HIV-1.
Journal of Immunology | 2007
Wassim M. Ballan; Bien-Aimee N. Vu; Brian R. Long; Christopher P. Loo; Jakob Michaëlsson; Jason D. Barbour; Lewis L. Lanier; Andrew Wiznia; Jacobo Abadi; Glenn J. Fennelly; Michael G. Rosenberg; Douglas F. Nixon
NK cells play an integral role in the innate immune response by targeting virally infected and transformed cells with direct killing and providing help to adaptive responses through cytokine secretion. Whereas recent studies have focused on NK cells in HIV-1-infected adults, the role of NK cells in perinatally HIV-1-infected children is less studied. Using multiparametric flow cytometric analysis, we assessed the number, phenotype, and function of NK cell subsets in the peripheral blood of perinatally HIV-1-infected children on highly active antiretroviral therapy and compared them to perinatally exposed but uninfected children. We observed an increased frequency of NK cells expressing inhibitory killer Ig-like receptors in infected children. This difference existed despite comparable levels of total NK cells and NK cell subpopulations between the two groups. Additionally, NK cell subsets from infected children expressed, with and without stimulation, significantly lower levels of the degranulation marker CD107, which correlates with NK cell cytotoxicity. Lastly, increased expression of KIR2DL3, NKG2C, and NKp46 on NK cells correlated with decreased CD4+ T-lymphocyte percentage, an indicator of disease severity in HIV-1- infected children. Taken together, these results show that HIV-1-infected children retain a large population of cytotoxically dysfunctional NK cells relative to perinatally exposed uninfected children. This reduced function appears concurrently with distinct NK cell surface receptor expression and is associated with a loss of CD4+ T cells. This finding suggests that NK cells may have an important role in HIV-1 disease pathogenesis in HIV-1-infected children.
The Journal of Infectious Diseases | 2007
Jennifer E. Snyder-Cappione; Douglas F. Nixon; Christopher P. Loo; Joan M. Chapman; Duncan A. Meiklejohn; Fernando F. Melo; Priscilla R. Costa; Johan K. Sandberg; Denise S. Rodrigues; Esper G. Kallas
Mycobacterium tuberculosis (MTB) is a leading cause of mortality worldwide from an infectious agent. Natural killer T (NKT) cells recognize mycobacterial antigens and contribute to anti-MTB immunity in mouse models. NKT cells were measured in subjects with pulmonary tuberculosis, MTB-exposed individuals, and healthy controls. NKT cell levels are selectively lower in peripheral blood mononuclear cells from individuals with pulmonary tuberculosis than in both MTB-exposed subjects and healthy control subjects. This apparent loss of NKT cells from the peripheral blood is sustained during the 6 months after the initiation of MTB treatment. These findings indicate that NKT cells may be an important component of antituberculosis immunity.
Clinical and Vaccine Immunology | 2008
Brian R. Long; Jakob Michaëlsson; Christopher P. Loo; Wassim M. Ballan; Bien-Aimee N. Vu; Frederick Hecht; Lewis L. Lanier; Joan M. Chapman; Douglas F. Nixon
ABSTRACT Recent studies indicate that innate immunity in influenza virus infection is an area of substantial importance for our understanding of influenza virus pathogenesis, yet our knowledge of the mechanisms controlling innate immunity remains limited. Further delineation of the roles of NK cells and innate immunity in viral infection may have important implications for the development of improved influenza virus vaccines. In this study, we evaluated the phenotype and function of NK and T lymphocytes, as well as influenza virus-specific immunoglobulin G production, prior to and following vaccination with the routinely administered trivalent influenza virus vaccine. We demonstrate influenza virus antigen-specific innate and adaptive cellular responses and evaluate changes in NK cell receptor expression over time. Our results demonstrate increased innate and adaptive cellular immune responses and show that NK cells are a significant source of gamma interferon (IFN-γ) following influenza virus vaccination. An increase in the frequency of IFN-γ-producing NK cells was observed in many subjects postvaccination. The subset distribution with respect to CD56dim and CD56bright NK cell subsets remained stable, as did the NK cell phenotype with respect to expression of cell surface activating and inhibitory receptors. These results may form the basis for further investigations of the role of NK cells in immunity to influenza.
AIDS | 2009
Jennifer E. Snyder-Cappione; Christopher P. Loo; Karina I. Carvalho; Carlotta Kuylenstierna; Steven G. Deeks; Frederick Hecht; Michael G. Rosenberg; Johan K. Sandberg; Esper G. Kallas; Douglas F. Nixon
Objective:Natural killer T (NKT) cells are efficiently targeted by HIV and severely reduced in numbers in the circulation of infected individuals. The functional capacity of the remaining NKT cells in HIV-infected individuals is poorly characterized. This study measured NKT cell cytokine production directly ex vivo and compared these responses with both the disease status and NKT subset distribution of individual patients. Methods:NKT cell frequencies, subsets, and ex-vivo effector functions were measured in the peripheral blood mononuclear cells of HIV-infected patients and healthy controls by flow cytometry. We measured cytokines from NKT cells after stimulation with either α-galactosyl ceramide-loaded CD1d dimers (DimerX-αGalCer) or phorbol myristate acetate and ionomycin. Results:The frequencies of NKT cells secreting interferon-γ and tumor necrosis factor-α were significantly lower in HIV-infected patients than healthy controls after DimerX-αGalCer treatment, but responses were similar after treatment with phorbol myristate acetate and ionomycin. The magnitude of the interferon-γ response to DimerX-αGalCer correlated inversely with the number of years of infection. Both interferon-γ and tumor necrosis factor-α production in response to DimerX-αGalCer correlated inversely with CD161 expression. Conclusion:The ex-vivo Th1 responses of circulating NKT cells to CD1d-glycolipid complexes are impaired in HIV-infected patients. NKT cell functions may be progressively lost over time in HIV infection, and CD161 is implicated in the regulation of NKT cell responsiveness.
The Journal of Infectious Diseases | 2008
Jakob Michaëlsson; Brian R. Long; Christopher P. Loo; Lewis L. Lanier; Gerald Spotts; Frederick Hecht; Douglas F. Nixon
Natural killer (NK) cells are believed to play a role in human immunodeficiency virus type 1 (HIV-1) disease progression, and NK cell levels are reduced in individuals with chronic HIV-1 infection. Interleukin (IL)-2 therapy results in an expansion of CD4(+) T cells as well as NK cells; however, little is known about the detailed effects of IL-2 therapy on NK cells in HIV-1 infection in general and in early infection in particular. Here, we investigated the effects of combined IL-2 therapy and antiretroviral therapy (ART) on the number, frequency, phenotype, and interferon (IFN)-gamma production of NK cells in individuals with early HIV-1 infection. Patients randomized to receive combined ART and IL-2 therapy predominantly expanded CD56(dim) NK cells, and the expansion was greater than in patients randomized to receive ART alone. Importantly, NK cell receptor expression and IFN-gamma production were maintained over time. This reconstitution of NK cells may be useful in helping contain viremia if patients discontinue therapy or develop drug resistance.
Clinical and Experimental Immunology | 2009
Lishomwa C. Ndhlovu; Jennifer E. Snyder-Cappione; Karina I. Carvalho; Fabio E. Leal; Christopher P. Loo; Fernanda R. Bruno; Aashish R. Jha; D. Devita; Aaron M. Hasenkrug; H. M. R. Barbosa; Aluisio Cotrim Segurado; Douglas F. Nixon; E. L. Murphy; Esper G. Kallas
Human T lymphotropic virus type 1 (HTLV‐1) infects 10–20 million people worldwide. The majority of infected individuals are asymptomatic; however, approximately 3% develop the debilitating neurological disease HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is also currently no cure, vaccine or effective therapy for HTLV‐1 infection, and the mechanisms for progression to HAM/TSP remain unclear. NK T cells are an immunoregulatory T cell subset whose frequencies and effector functions are associated critically with immunity against infectious diseases. We hypothesized that NK T cells are associated with HAM/TSP progression. We measured NK T cell frequencies and absolute numbers in individuals with HAM/TSP infection from two cohorts on two continents: São Paulo, Brazil and San Francisco, CA, USA, and found significantly lower levels when compared with healthy subjects and/or asymptomatic carriers. Also, the circulating NK T cell compartment in HAM/TSP subjects is comprised of significantly more CD4+ and fewer CD8+ cells than healthy controls. These findings suggest that lower numbers of circulating NK T cells and enrichment of the CD4+ NK T subset are associated with HTLV‐1 disease progression.
Scandinavian Journal of Immunology | 2011
Carlotta Kuylenstierna; Jennifer E. Snyder-Cappione; Christopher P. Loo; Brian R. Long; Veronica D. Gonzalez; Jakob Michaëlsson; Markus Moll; Gerald Spotts; Frederick Hecht; Douglas F. Nixon; Johan K. Sandberg
Cytokine immunotherapy is being evaluated as adjunct treatment in infectious diseases. The effects on innate and adaptive immunity in vivo are insufficiently known. Here, we investigate whether combination treatment with antiretroviral therapy (ART) and Interleukin‐2 (IL‐2) of patients with primary HIV‐1 infection induces sustained increases in circulating NKT cell and NK cell numbers and effector functions and investigate how changes are coordinated in the two compartments. Patients with primary HIV‐1 infection starting ART were analyzed for numbers, phenotype and function of NKT cells, NK cells and dendritic cells (DC) in peripheral blood before, during and after IL‐2 treatment. NKT cells expanded during IL‐2 treatment as expected from previous studies. However, their response to α‐galactosyl ceramide antigen were retained but not boosted. Myeloid DC did not change their numbers or CD1d‐expression during treatment. In contrast, the NK cell compartment responded with rapid expansion of the CD56dim effector subset and enhanced IFNγ production. Expansions of NKT cells and NK cells retracted back towards baseline values at 12 months after IL‐2 treatment ended. In summary, NKT cells and NK cells respond to IL‐2 treatment with different kinetics. Effects on cellular function are distinct between the cell types and the effects appear not to be sustained after IL‐2 treatment ends. These results improve our understanding of the effects of cytokine immunotherapy on innate cellular immunity in early HIV‐1 infection.